GTBP
GT Biopharma, Inc.
Key Financials
Operating Income
$-12422000
↓ 82.0%
Net Income
$-28354000
↓ 25.2%
Revenue
$0
NaN%
EPS (Diluted)
$-6.68
↑ 24.9%
Total Assets
$8.1M
↑ 87.6%
Total Liabilities
$1.3M
↓ 95.7%
Gross Profit
$0
NaN%
Shareholders' Equity
$5.8M
↑ 92.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/15/2026 | View on SEC |
| EFFECT | 5/13/2026 | View on SEC |
| 424B3 | 5/13/2026 | View on SEC |
| S-1 | 4/30/2026 | View on SEC |
| 8-K | 4/7/2026 | View on SEC |
| 10-Q/A | 3/6/2026 | View on SEC |
| 10-Q/A | 3/6/2026 | View on SEC |
| 10-K | 3/2/2026 | View on SEC |
| 8-K | 3/2/2026 | View on SEC |
| EFFECT | 1/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GTBP |
| Company Name | GT Biopharma, Inc. |
| CIK | 109657 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (800) 304-9888 |